b7a bsigg
Animal productexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03040687)
Timeline
Indications
Mechanism of action
- Escherichia coliImmunity, passive
Escherichia coli immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- b7a bsigg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06692907 | Phase 2 | Jan 13, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03040687 | Phase 1 | Jan 1, 2017 | Department of Defense, Johns Hopkins University, United States Navy |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2017 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2025 |
| United States Navy | Government | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1